Volume 44, Issue 5 pp. 837-845
ORIGINAL ARTICLE

Effect of the sequence of pull of bone marrow aspirates on plasma cell quantification in plasma cell proliferative disorders

Garima Jain

Garima Jain

Department of Laboratory Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India

Search for more papers by this author
Nupur Das

Nupur Das

Department of Laboratory Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India

Search for more papers by this author
Smeeta Gajendra

Smeeta Gajendra

Department of Laboratory Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India

Search for more papers by this author
Satya Prakash Gangwar

Satya Prakash Gangwar

Department of Laboratory Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India

Search for more papers by this author
Ritu Gupta

Corresponding Author

Ritu Gupta

Department of Laboratory Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India

Correspondence

Ritu Gupta, Department of Laboratory Oncology, Room No. 239, Second Floor, Dr BRAIRCH, All India Institute of Medical Sciences, New Delhi 110029, India.

Email: [email protected]

Search for more papers by this author
Saumyaranjan Mallik

Saumyaranjan Mallik

Department of Pathology, AIIMS, New Delhi, India

Search for more papers by this author
Atul Sharma

Atul Sharma

Department of Medical Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India

Search for more papers by this author
Lalit Kumar

Lalit Kumar

Department of Medical Oncology, Dr. BRAIRCH, AIIMS, New Delhi, India

Search for more papers by this author
Ashish Datt Upadhyay

Ashish Datt Upadhyay

Department of Biostatistics, AIIMS, New Delhi, India

Search for more papers by this author
First published: 15 June 2022
Citations: 2

Funding information: Department of Biotechnology, Ministry of Science and Technology, India, Grant/Award Number: BT/MED/30/SP11006/2015

Abstract

Introduction

The evaluation of plasma cell (PC) compartment is influenced by the quality of bone marrow aspirate (BMA). Herein, we evaluated the impact of sequence of pull on quality of clinical assessment in plasma cell proliferative disorders (PCPDs).

Methods

Histomorphology along with smears from first pull and second pull BMA and flow cytometric immunophenotyping (FCMI) data from second pull aspirate were evaluated for cellularity and PC%.

Results

Of the 484 samples, BMA smears were adequate in 87.4% of first pull (median PC = 7%; IQR = 2–25%) and 51.2% of second pull samples (median PC = 2%; IQR = 0.5–12%; p < 0.001). Recovery of PC was least on FCMI (median PC = 0.59%; IQR = 0.14–3.07%), however, sample adequacy was met in 42.6% of samples with acquisition of ≥3 million events. Second pull smears under-reported PC% in 34% of newly diagnosed multiple myeloma (NDMM) (<10% PC) and 46% of MM on therapy (<5% PC), resulting in suboptimal assessment. Bone marrow biopsy (BMBx) was evaluated in a total of 309 cases (median PC = 10.0%; IQR 4.0–40.0%) with significantly higher numbers of BMPC% on BMBx compared with first pull smears (Mean ± 2SD: 25.9% ± 30.54 vs. 20.77% ± 20.20; p = 0.001).

Conclusion

First pull BMA smears were of superior quality but inadequate in one-tenth of samples. Second pull smears underreported PC% and recovery of PC compartment was poorest on FCMI. Concurrent bone marrow biopsy and use of the first pull sample for FCMI along with acquisition of a higher number of cells on FCMI may enhance the quality of assessment in PCPDs.

CONFLICT OF INTEREST

None declared.

DATA AVAILABILITY STATEMENT

Author elects to not share data.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.